Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Inclusion Criteria:

1. Eighteen years and older;
2. Histological or cytological diagnosis of unresectable or metastatic gallbladder cancer or cholangiocarcinoma;
3. Previously untreated with systemic therapy; Subjects who developed recurrent disease >6 months after a sort of adjuvant, neoadjuvant chemotherapy could also be eligible.
4. Liver function Child-Pugh A or B;
5. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;
6. Life expectancy of at least 12 weeks;
7. At least one measurable lesion per RECIST 1.1;
8. Adequate organ function

Exclusion Criteria:

1. Specific anti-tumor treatment prior to 4 weeks;
2. more than 50% liver metastasis ;
3. Patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection etc;
4. History of severe hypersensitivity reaction to any monoclonal antibody or chemistry;
5. Women who are pregnant or in the period of lactation;
6. Patients with an active, known or suspected autoimmune disease. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement;